Download PDFPDF
Intraocular pressure–lowering medications during pregnancy and risk of neonatal adverse outcomes: a propensity score analysis using a large database
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Management of Glaucoma During Pregnancy
    • Angelo P. Tanna, Professor and Vice Chair of Ophthalmology Northwestern University Feinberg School of Medicine

    Title: Management of Glaucoma During Pregnancy

    Author: Angelo P. Tanna

    Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Division of Ophthalmology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois, USA

    Conflicts of Interest Disclosure:
    APT: Consultant to Ivantis, Sandoz, and Zeiss

    APT is supported by an unrestricted departmental grant from Research to Prevent Blindness, NY, NY

    Corresponding Author:
    Angelo P. Tanna, M.D.
    Department of Ophthalmology
    Northwestern University Feinberg School of Medicine
    645 N. Michigan Ave., Suite 440
    Chicago, IL 60611
    Telephone: 312-908-8152
    Fax: 312-503-8152

    Dear Editor:

    I read with interest the work of Doctor Hashimoto and colleagues on the risk of adverse neonatal outcomes (congenital anomalies, preterm birth, low birth weight) associated with maternal exposure to intraocular pressure-lowering medications during pregnancy.1 They used a large Japanese claims database and state-of-the-art statistical methodology to evaluate the frequency of adverse events in a cohort of live births of 91 women who had “at least one dispensation of IOP-lowering medications during the first trimester,” compared to that observed in 735 women with glaucoma or...

    Show More
    Conflict of Interest:
    Consultant to Sandoz, Ivantis and Zeiss